Joshua K. Sabari, MD

Joshua K. Sabari, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine. He is also medical director, ofThoracic Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center.

Articles

Utilizing pCR, MPR, and Other Clinical Indicators to Guide Adjuvant Treatment Decisions in Early-Stage NSCLC

May 21st 2025

Panelists discuss how to treat patients who do not achieve a pathological complete response or major pathological response after neoadjuvant chemoimmunotherapy, considering options such as adjuvant therapy, close surveillance, or clinical trial enrollment based on individual risk factors and disease characteristics.

Leveraging MRD Testing to Guide Treatment Decisions in Early-Stage Resectable NSCLC

May 21st 2025

Panelists discuss how circulating tumor DNA could serve as a potential marker for minimal residual disease (MRD) in this setting, offering a noninvasive and sensitive method for monitoring treatment response and detecting relapse.

Dr Sabari on the Activity of Zongertinib in Pretreated, Advanced, HER2-Mutated NSCLC

May 15th 2025

Joshua K. Sabari, MD, discusses how phase 1 efficacy data with zongertinib in HER2-mutant NSCLC lay the foundation for future research with the agent.

Evolving Targeted Therapy Approaches in Resectable Early-Stage NSCLC With Actionable Mutations

May 14th 2025

Panelists discuss how medical professionals are integrating targeted therapies, such as those for EGFR, ALK, and other mutations like RET and ROS1, into the treatment of resectable early-stage non–small cell lung cancer (NSCLC), with a focus on incorporating the ADAURA and ALINA regimens into clinical practice.

Expert Insights and Clinical Decision-Making: Neoadjuvant and Perioperative Strategies in Early-Stage NSCLC

May 14th 2025

Panelists discuss how medical professionals identify patients who should receive neoadjuvant immune checkpoint inhibitors (ICI) before surgery based on tumor characteristics, patient health, and treatment response, and how factors such as surgical outcomes, recurrence risk, and molecular markers guide decisions on the need for additional adjuvant therapy post surgery.

Navigating the Evolving Treatment Landscape for Early-Stage NSCLC: Personalizing Care Through Biomarker-Guided Strategies and Multidisciplinary Approaches

May 7th 2025

Panelists discuss how the latest efficacy and safety data from AEGEAN, CheckMate 816, CheckMate 77T, and KEYNOTE-671, along with recent approvals in early-stage non–small cell lung cancer (NSCLC) treatment, are shaping optimized treatment approaches and influencing clinical practice.

Enhancing Early-Stage NSCLC Diagnosis: Leveraging Pathology and Imaging for Accurate Staging

May 7th 2025

Panelists discuss how a multidisciplinary team—including oncologists, thoracic surgeons, radiologists, and pathologists—collaborates to streamline the diagnostic process for patients with resectable non–small cell lung cancer (NSCLC), ensuring timely evaluation, accurate staging, and personalized treatment planning.

A Focus on the Role of Patient Navigators in the Diagnosis and Management of Early-Stage NSCLC

April 30th 2025

Panelists discuss how a multidisciplinary team (MDT) approach to resectable non–small cell lung cancer (NSCLC) involves an initial diagnostic workup with imaging (CT, PET-CT), histologic confirmation via biopsy, staging with mediastinal assessment (endobronchial ultrasound or mediastinoscopy), and timely molecular testing (eg, EGFR, ALK, PD-L1) integrated early in the process to guide perioperative treatment decisions.

Expert Insights and Best Practices in Diagnosing Resectable Early-Stage NSCLC

April 30th 2025

Panelists discuss how a multidisciplinary approach enhances the early diagnosis of non–small cell lung cancer (NSCLC) by integrating insights from oncology, radiology, pathology, and surgery.

Comprehensive Biomarker Testing in Early-Stage NSCLC: Identifying Gaps, Challenges, and Strategies for Improvement

April 23rd 2025

Panelists discuss how comprehensive biomarker testing in early-stage disease settings provides crucial molecular insights that guide surgical planning and inform critical decisions about neoadjuvant, perioperative, and adjuvant treatment strategies.

Optimizing Molecular Testing, Diagnosis, and Workflow in Early-Stage NSCLC Through Multidisciplinary Collaboration

April 23rd 2025

Panelists discuss how collaboration between pathologists, oncologists, and pulmonologists is essential for timely next-generation sequencing (NGS) testing in early-stage non–small cell lung cancer (NSCLC), emphasizing that molecular testing should ideally be ordered at diagnosis with prioritization of EGFR, ALK, ROS1, BRAF, MET, KRAS, RET, and NTRK biomarkers to guide treatment decisions before surgical intervention.

Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC

April 16th 2025

Panelists discuss how medical professionals frequently encounter tissue adequacy challenges in comprehensive genomic profiling for early-stage non–small cell lung cancer (NSCLC), employing strategies such as optimized biopsy techniques, efficient tissue triage protocols, and complementary liquid biopsies to ensure sufficient material for complete molecular analysis.

Comprehensive Molecular Testing in Early-Stage NSCLC: Best Practices and Multidisciplinary Strategies

April 16th 2025

Panelists discuss how medical professionals currently approach molecular testing in early-stage non–small cell lung cancer (NSCLC) through comprehensive biomarker analysis, including targeted next-generation sequencing (NGS), to identify actionable mutations that guide adjuvant therapy decisions and improve patient outcomes.

Dr Sabari on Considerations for Conducting and Interpreting HER2 Testing in NSCLC

February 14th 2025

Joshua K. Sabari, MD, discusses key considerations when testing for HER2 alterations in non–small cell lung cancer

Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

September 4th 2024

Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

August 8th 2024

The panel discusses treatment considerations for consolidation durvalumab.

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

August 8th 2024

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

August 8th 2024

The panel looks at a second patient case study.

Management of Resectable Early Stage NSCLC with Actionable Mutations

August 8th 2024

The panel discusses management of resectable early-stage non–small cell lung cancer.

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

August 8th 2024

The panel discusses the factors that go into selecting patients for adjuvant therapy.